

Variant: *NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)*

Version: 2.0

[CA119170](#)

[7947 \(ClinVar\)](#)

Gene: MYOC ([HGNC:4653](#))

Condition: open-angle glaucoma ([MONDO:0005338](#))

Inheritance Mode: Autosomal dominant inheritance

UID: 30a3432f-835c-4e0b-942a-7a84d0c5f07c

Approved on: 2026-01-21

Published on: 2026-01-20

HGVS expressions

NM_000261.2:c.1091G>T

NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)

NC_000001.11:g.171636349C>A

CM000663.2:g.171636349C>A

NC_000001.10:g.171605489C>A

CM000663.1:g.171605489C>A

NC_000001.9:g.169872112C>A

NG_008859.1:g.21285G>T

ENST00000037502.11:c.1091G>T

ENST00000637303.1:c.235-2281C>A

ENST00000638471.1:c.*429G>T

ENST00000037502.10:c.1091G>T

ENST00000614688.1:c.*55G>T

NM_000261.1:c.1091G>T

Pathogenic

Met criteria codes **5**

PP1_Strong **PP3_Moderate**

PS4_Supporting **PS3_Moderate**

PM2_Supporting

Not Met criteria codes **9**

BS1 **BS3** **BP4** **BP7** **PS1** **PS2**

BA1 **PM5** **PM4**

Evidence Links **4**

Expert Panel

[Glaucoma VCEP](#)

Criteria Specification Information

Criteria Specification: *ClinGen Glaucoma Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MYOC Version 2.0.0*

Criteria Specification Approval History

Criteria Specifications for this VCEP















Evidence submitted by expert panel

Glaucoma VCEP






The c.1091G>T variant in MYOC is a missense variant predicted to cause substitution of Glycine by Valine at amino acid 364 (p.Gly364Val). This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles. The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function. The Gly364Val protein had increased instability and reduced secretion levels compared to













wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met. 18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥ 7 meioses in >1 family). 2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands). In summary, this variant met the criteria to receive a score of 10 and to be classified as pathogenic (pathogenic classification ≥ 10 , adapted from PMID: 32720330) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v2.0.0, 5 Dec 2024): PP1_Strong, PS3_Moderate, PP3_Moderate, PS4_Supporting, PM2_Supporting.

Met criteria codes

PP1_Strong			18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥ 7 meioses in >1 family).
PP3_Moderate			The REVEL score = 0.896, which was within the 0.773-0.931 range for PP3_Moderate, predicting a damaging effect on MYOC function.
PS4_Supporting			2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands).
PS3_Moderate			<p>The Gly364Val protein had increased instability and reduced secretion levels compared to wild type myocilin protein in these studies (PMIDs: 16466712, 21612213, 23129764). The assays met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. This protein has also been assessed in these other studies (PMIDs: 10545602, 11152659, 15069026, 16297911), however, the same level of evidence was not met.</p> <hr/> <p>The Gly364Val protein is unstable. The assay in this study meets the OddsPath threshold for PS3_Moderate (> 4.3) (when combined with PMIDs: 20334347, 21612213, 25524706, 36579626). PubMed:23129764 </p> <p>The Gly364Val protein is insoluble. The assay in this study does not meet the OddsPath threshold for PS3_Supporting (> 2.1). PubMed:15069026 </p> <p>The Gly364Val protein is unstable. Note: this is a duplicated result from PMID: 23129764 PubMed:25524706 </p> <p>The Gly364Val protein is unstable. The assay in this study meets the OddsPath threshold for PS3_Moderate (> 4.3) (when combined with PMIDs: 20334347, 23129764, 25524706, 36579626). PubMed:21612213 </p>
PM2_Supporting			This variant was not found in any genetic ancestry group of gnomAD (v4.1.0), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a genetic ancestry group of at least 10,000 alleles.

Not Met criteria codes

BS1			This criterion was not met as PM2_Supporting has been met.
BS3			This criterion was not met as PS3_Moderate has been met.
BP4			This criterion was not met as PP3_Moderate has been met.

BP7			This criterion did not apply to this variant.
PS1			An established LP or P variant causing this same amino acid change has not been identified.
PS2			This variant has not been identified de novo.
BA1			This criterion was not met as PM2_Supporting has been met.
PM5			No other LP or P missense variants at this amino acid residue have been identified.
PM4			This criterion did not apply to this variant.

Curation History [↗](#)

Showing 1 to 3 of 3 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.